Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study
Open Access
- 1 September 2016
- journal article
- research article
- Published by SAGE Publications in Cell Transplantation
- Vol. 25 (9) , 1701-1711
Abstract
An increasing number of patients have refractory angina despite optimal medical therapy and are without further revascularization options. Preclinical studies indicate that human CD34+ stem cells can stimulate new blood vessel formation in ischemic myocardium, improving perfusion and function. In ACT34-CMI ( N = 167), patients treated with autologous CD34+ stem cells had improvements in angina and exercise time at 6 and 12 months compared to placebo; however, the longer-term effects of this treatment are unknown. ACT34 was a phase II randomized, double-blind, placebo-controlled clinical trial comparing placebo, low dose (1 × 105 CD34/kg body weight), and high dose (5 × 105 CD34/kg) using intramyocardial delivery into the ischemic zone following NOGA® mapping. To obtain longer-term safety and efficacy in these patients, we compiled data of major adverse cardiac events (MACE; death, myocardial infarction, acute coronary syndrome, or heart failure hospitalization) up to 24 months as well as angina and quality of life assessments in patients who consented for 24-month follow-up. A total of 167 patients with class III–IV refractory angina were randomized and completed the injection procedure. The low-dose-treated patients had a significant reduction in angina frequency ( p = 0.02, 0.035) and improvements in exercise tolerance testing (ETT) time ( p = 0.014, 0.017) compared to the placebo group at 6 and 12 months. At 24 months, patients treated with both low-and high-dose CD34+ cells had significant reduction in angina frequency ( p = 0.03). At 24 months, there were a total of seven deaths (12.5%) in the control group versus one (1.8%) in the low-dose and two (3.6%) in the high-dose ( p = 0.08) groups. At 2 years, MACE occurred at a rate of 33.9%, 21.8%, and 16.2% in control, low-, and high-dose patients, respectively ( p = 0.08). Autologous CD34+ cell therapy was associated with persistent improvement in angina at 2 years and a trend for reduction in mortality in no-option patients with refractory angina.Keywords
This publication has 24 references indexed in Scilit:
- Treatment of refractory angina in patients not suitable for revascularizationNature Reviews Cardiology, 2013
- Stem Cell Therapy Is a Promising Tool for Refractory Angina: A Meta-analysis of Randomized Controlled TrialsCanadian Journal of Cardiology, 2013
- Meta-Analysis of Stem Cell Therapy in Chronic Ischemic CardiomyopathyThe American Journal of Cardiology, 2013
- Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Long-term survival in patients with refractory anginaEuropean Heart Journal, 2013
- Management of Patients With Refractory Angina: Canadian Cardiovascular Society/Canadian Pain Society Joint GuidelinesCanadian Journal of Cardiology, 2012
- Dose-Dependent Contribution of CD34-Positive Cell Transplantation to Concurrent Vasculogenesis and Cardiomyogenesis for Functional Regenerative Recovery After Myocardial InfarctionCirculation, 2006
- Therapeutic Angiogenesis and Vasculogenesis for Ischemic DiseaseCirculation, 2004
- The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory AnginaEuropean Heart Journal, 2002
- Isolation of Putative Progenitor Endothelial Cells for AngiogenesisScience, 1997